Nuvation Bio
NUVB
233 hedge funds and large institutions have $947M invested in Nuvation Bio in 2026 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 91 increasing their positions, 57 reducing their positions, and 37 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 57
45% more call options, than puts
Call options by funds: $5.27M | Put options by funds: $3.64M
32% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 37
4% more funds holding
Funds holding: 223 → 233 (+10)
2.03% more ownership
Funds ownership: 61.63% → 63.65% (+2%)
44% less funds holding in top 10
Funds holding in top 10: 9 → 5 (-4)
50% less capital invested
Capital invested by funds: $1.89B → $947M (-$945M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DFO
Duquesne Family Office
New York
|
+$25.3M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$15.9M |
| 3 |
Two Sigma Investments
New York
|
+$10.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$10.8M |
| 5 |
AG
Algert Global
San Francisco,
California
|
+$8.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CFM
Capricorn Fund Managers
London,
United Kingdom
|
-$14.2M |
| 2 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
-$14.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.4M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$13M |
| 5 |
SCP
SymBiosis Capital Partners
Bentonville,
Arkansas
|
-$11.2M |
NUVB Hedge Fund Activity: Q1 2026 in Review
233 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q1 2026, worth a combined $947M — down 50% from $1.89B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new NUVB positions and 37 closed out — a net gain of 12 holders — while 91 added to existing stakes and 57 trimmed.
The largest buyer was Duquesne Family Office, opening a new position worth an estimated $25.3M. The largest seller was Capricorn Fund Managers, exiting entirely with an estimated $14.2M sold.
- 233 institutional investors held Nuvation Bio (NUVB) as of Q1 2026, up from 223 in Q4 2025.
- Funds reported $947M of Nuvation Bio stock for Q1 2026, down 50% quarter-over-quarter.
- 49 funds opened new Nuvation Bio positions in Q1 2026 and 37 closed out, a net change of +12 holders.
- The largest Nuvation Bio buyer in Q1 2026 was Duquesne Family Office, an estimated $25.3M added.
- The largest Nuvation Bio seller in Q1 2026 was Capricorn Fund Managers, an estimated $14.2M sold.
Based on aggregated 13F filings for Q1 2026.